
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics is a biotechnology company with a positive outlook due to their innovative approach to restoring protein expression using RNA medicine, as well as their strong pipeline with multiple potential disease-modifying therapies. The recent enrollment of 150 patients for their P3 trial and the potential for early FDA approval based on beyond-seizure effects of their first medicine, zorevunersen, indicate strong operational excellence and transformational potential. Based on our valuation analysis, we believe the stock is undervalued and have set a 12-month price target of $35 per share. However, the company still faces risks such as clinical readouts, regulatory uncertainty, and potential patent disputes.
Bears say
Stoke Therapeutics is facing several risks that may affect its success, including low likelihood of success in attaining regulatory approval for its drug candidates and dependence on third-party data. Additionally, the company will need to raise additional capital before it becomes profitable, which may result in share dilution for shareholders. The high volatility of the stock price and potential challenges in gaining market acceptance for its products may also impact the company's overall financial outlook.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares